Why the study?
Do renin-angiotensin system blockers and statins have beneficial pleiotropic effects beyond their primary mechanisms in cardiovascular risk management?
Do renin-angiotensin system blockers and statins have beneficial pleiotropic effects beyond their primary mechanisms in cardiovascular risk management?
This review highlights the pleiotropic effects of statins and RAS blockers, such as endothelial restoration and anti-proliferative properties, which contribute to cardiovascular risk reduction.
The renin-angiotensin system (RAS) and dyslipidaemia have been shown to be involved in the genesis and progression of atherosclerosis. Manipulation of the RAS has been effective in modifying human coronary artery disease progression. Similarly, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors or statins have been shown to reduce cholesterol and lower cardiovascular events in primary and secondary prevention trials in coronary artery disease. In addition to their primary mode of action, statins and blockers of the RAS possess common additional properties that include restoration of endothelial activity and inhibition of cellular proliferation. This article reviews the current data on the common properties of these classes of drugs in which the beneficial effects extend beyond their antihypertensive and lipid-lowering properties.
No takes yet. Share an insight, caveat, or question.
Chiong et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: